Neumora Therapeutics (NASDAQ: NMRA) president sells shares to cover taxes

Rhea-AI Filing Summary

Neumora Therapeutics President Joshua Pinto reported a Form 4 showing the sale of 5,967 shares of common stock at $3.535 per share on February 17, 2026. According to the footnote, the shares were sold solely to satisfy tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, Pinto directly holds 57,783 shares, and an additional 152,167 shares are held indirectly by Maple DE Holdings LLC.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Joshua

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL WAY, SUITE 1

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		5,967	D	$3.535	57,783	D
Common Stock								152,167	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

2. Shares held by Maple DE Holdings LLC.

	/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Neumora Therapeutics (NMRA) report for Joshua Pinto?

Neumora Therapeutics reported that President Joshua Pinto sold 5,967 shares of common stock at $3.535 per share. The filing states this sale was to cover tax withholding obligations arising from the vesting of restricted stock units.

Why did Neumora’s president sell 5,967 NMRA shares on February 17, 2026?

The sale of 5,967 shares on February 17, 2026 was disclosed as being made to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than as a discretionary open-market sale for portfolio or liquidity reasons.

How many Neumora Therapeutics (NMRA) shares does Joshua Pinto hold after the reported sale?

After the reported tax-related sale, Joshua Pinto directly holds 57,783 shares of Neumora common stock. The filing also shows an additional 152,167 shares held indirectly through Maple DE Holdings LLC, which are reported as indirect ownership.

How were indirect NMRA share holdings reported in Joshua Pinto’s Form 4?

The Form 4 lists 152,167 shares of Neumora common stock as indirectly owned, with a footnote stating these shares are held by Maple DE Holdings LLC. This indicates a separate entity associated with Pinto holds those shares, rather than direct individual ownership.

Does the Neumora (NMRA) Form 4 indicate multiple transaction types for Joshua Pinto?

Yes. The Form 4 shows one sale transaction of 5,967 shares to cover tax withholding and a separate line reflecting indirect holdings of 152,167 shares through Maple DE Holdings LLC, which is presented as an ownership disclosure rather than a trade.